A 6-year study of the link between alcohol consumption and spinal radiographic progression in axial spondyloarthritis (axSpA). Results indicate that alcohol may worsen spinal damage, particularly in males and those with radiographic axSpA. Future research should explore… https://t.co/IIvTyq7kBe

• https://x.com/i/web/status/1857830999583080712

Using #MachineLearning for predicting flares in axSpA @DiegoBenavent et al, data from METEOR-SpA registry showed the ff predictors of flares thru the reduced logistic regression model: 🔅lower ASDAS 🔅enthesitis 🔅prior flares 🔅longer treatment duration @RheumNow #ACR24 abs559 https://t.co/wyIo9gnKVJ

• https://x.com/RHEUMarampa/status/1857830422023123171/photo/1

📈 Data from @UIowa_Rheum on how rurality impacts delay to diagnosis in #GCA 📍 0747 👉🏼 People living in more rural areas have an increased time to diagnosis & treatment- further prospective studies needed to delineate effects of rurality further @RheumNow #ACR24 @LemonReneeNi https://t.co/3YMcI9ha3T

• https://x.com/DrMiniDey/status/1857830313071677758/photo/1

Harkins @DrTrishHarkins et al. People with PMR exhibit an accelerated physical aging phenotype at baseline. High rates of frailty (41%), pre-frailty (28%), cognitive impairment (74%!), sarcopenia (23%), osteoporosis (21%) @RheumNow #ACR24 Abstr#0740 https://t.co/4ZT8VtGi1W https://t.co/xBQ5CLlb5A

• Evaluation of an Accelerated Physical Aging Phenotype in Newly Diagnosed Patien…
• https://x.com/RichardPAConway/status/1857830238534635630/photo/1

Does apremilast have cardiometabolic benefits? Abstract 0598: In PsA patients, 1-year treatment with apremilast associated w/ ↓ body fat mass, including android fat, and was linked w/ improved disease activity (DAS28-CRP). #ACR24 @RheumNow https://t.co/11n4gQN7Xo

• https://x.com/AkhilSoodMD/status/1857829735235035286/photo/1

Characteristics of difficult-to-treat AS accdg to a retrospective study by @DaoudAnsaam @mmagrey1 et al ⬆️ BMI + comorbidities: HTN, CKD, depression + EAMs: IBD, Pso, iridocyclitis + HLA-B27 Interesting real world data. @RheumNow #ACR24 abs573 https://t.co/GlE4tFpsSz

• https://x.com/RHEUMarampa/status/1857829538748571674/photo/1

FDA has given FDA Breakthrough Therapy designation to Nipocalimab for treatment of adults w/ moderate-to-severe Sjögren’s disease. NIPO is an Ab to neonatal Fc receptor (FcRn), & was tested and shown effective in Sjog in the Phase 2 DAHLIAS study - a plenary presentation at… https://t.co/aQDp7iPKXD https://t.co/hJ8fe6JwxC

#0588 🔬 Sex Differences in PsA ➡️n=1405, pooled RCT data ♀️49%: Milder PsO (PASI 7.8 v 11.5), higher BMI, longer PsA duration,⬆️ fatigue/pain vs ♂️ ♀️worse QoL/functional impairment ♂️More dactylitis (45% v 37%) 🩺 Sex-specific factors matter in PsA #ACR24 @RheumNow

Puechal et al. Serial ANCA testing may predict relapse in a large group of AAV patients but is NOT useful for individual patients. @RheumNow #ACR24 Abstr#0721 https://t.co/ClvTk2Tlar https://t.co/k4vc7l9jzK

• Does Serial ANCA Testing Help Predict the Risk of Relapse in Granulomatosis wit…
• https://x.com/RichardPAConway/status/1857827722002571721/photo/1

#0589 🔬Time to Response in PsA Domains: Secukinumab ➡️Post-hoc analyses, n=1366 🔑Median time (wks) to MCID 👇 🔴Systemic inflammation <2 🔴MSK: ~4 wks (enthesitis~12) 🔴Fatigue~7–8 🔴PASI75~8–12; nails ~24 🩺 Rapid MSK & QoL benefits precede skin/nail #ACR24 @RheumNow https://t.co/WfqkryA1CC

• https://x.com/CaoilfhionnMD/status/1857827721856037222/photo/1

Data from the study by Dr. Aguilar et al showed that high dose NSAID use was not assoc'd with incident HTN in their cohort of early axSpA patients. Shows important role of NSAIDs in #axSpA but still should be used judiciously @RheumNow #ACR24 abs540 @rheum_cat @rheumarhyme https://t.co/LK5yFZynu4

• https://x.com/RHEUMarampa/status/1857827589999526276/photo/1

Switching vs cycling - which is better? In PsA & axSpA, a real-world analysis shows that switching to IL-17Ai after TNFi discontinuation may lead to similar or better outcomes compared to cycling to another TNFi. Data from the CorEvitas PsA/SpA Registry. Abstr#0585.… https://t.co/AJP4NBjmzr

• https://x.com/i/web/status/1857827218912849961

De Lorenzis et al. MMF in LcSSc. Target Trial Emulation. 1435 patients. Incidence vasodilator treatment escalation over 41 months, 1/100py in MMF vs 7.3/100py in controls. @RheumNow #ACR24 Abstr#0688 https://t.co/D3qTUHyIIc https://t.co/6azvaS0ElL

• Mycophenolate Mofetil Treatment in Limited Cutaneous Systemic Sclerosis Reduces…
• https://x.com/RichardPAConway/status/1857826212040573293/photo/1

Galloway et al report OCP/HRT use in RA is not associated with VTE in UK population based study. Increased risk by having RA, HR 1.52. Risk OCP HR 1.43, HRT HR 2.32 - neither statistical significant but very wide CI's! Hmm... @RheumNow #ACR24 Abstr#0134 https://t.co/CZNoRfYWe8 https://t.co/uC6jA9lcX9

• Use of Oral Contraceptives in Females with Rheumatoid Arthritis Is Not Associat…
• https://x.com/RichardPAConway/status/1857825456986476845/photo/1

The risk of discontinuing first line biologics was twice higher in non-radiographic female patients compared to males. Abstr#0572 @RheumNow #ACR24 https://t.co/1tQUhsbqUu

• https://x.com/synovialjoints/status/1857825346197852220/photo/1